Skip to main navigation

Sagimet Biosciences

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

News Releases

Year

9/4/2024

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

8/14/2024

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

8/1/2024

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

6/10/2024

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

6/6/2024

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

5/16/2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

5/15/2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

5/7/2024

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

5/6/2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

4/22/2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Site Map

About
Science
Investors
Programs
Contact

Contact Us

Business Development:
bd@sagimet.com

Investors:
ir@sagimet.com

Media:
media@sagimet.com

© 2024 Sagimet Biosciences Inc. All Rights Reserved.

Close line1 Close line2

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact